(Q34463421)

2 August 2017

1 reference

title

Management of treatment resistance in schizophrenia (English)

1 reference

2 August 2017

0 references

Conley RR

1

1 reference

PubMed ID

11743944

2 August 2017

Kelly DL

series ordinal

2

1 reference

PubMed ID

11743944

2 August 2017

language of work or name

English

0 references

publication date

1 December 2001

1 reference

2 August 2017

Biological Psychiatry

1 reference

2 August 2017

50

1 reference

2 August 2017

898-911

1 reference

2 August 2017

11

1 reference

Adjunctive risperidone treatment in patients with 'clozapine-resistant schizophrenia'

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Long-term reserpine use in selected refractory outpatients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Effect of adjuvant reserpine treatment on catecholamine metabolism in schizophrenic patients under long-term neuroleptic treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

7 January 2021

Clozapine in aggression

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Defining treatment refractoriness in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Successful outcome using quetiapine in a case of treatment-resistant schizophrenia with assaultive behavior

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Catching up on schizophrenia. The Fifth International Congress on Schizophrenia Research, Warm Springs, Va, April 8-12, 1995.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Schizophrenia: improving outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Patient response and resource management: another view of clozapine treatment of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Clozapine augmentation: safety and efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

When Symptoms Persist: Choosing Among Alternative Somatic Treatments for Schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Lithium Carbonate, Haloperidol, and Irreversible Brain Damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Clinical action of remoxipride

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Time to clozapine response in a standardized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Effect of risperidone on hostility in schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Antipsychotic drugs: clinical pharmacology and therapeutic use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Addition of risperidone to clozapine therapy in chronically psychotic inpatients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Conventional antipsychotic medications for schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Combined treatment of schizophrenic psychoses with haloperidol and valproate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Clozapine plus lamotrigine in treatment-resistant schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Olanzapine for patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Mental disorders and homicidal behavior in Finland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Clozapine eligibility among state hospital patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Determinants of medication compliance in schizophrenia: empirical and clinical findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

An open comparison of clozapine and risperidone in treatment-resistant schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

A double-blind comparison of valproate and lithium in the treatment of acute mania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

High Potency Neuroleptics and Violence in Schizophrenics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Itil TM, Keskiner A, Fink M: Thioridazine and chlordiazepoxide, alone and combined, in the treatment of chronic schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Effects of stringent criteria on eligibility for clozapine among public mental health clients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Combined electroconvulsive therapy and clozapine in treatment-resistant schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Psychopharmacologic treatment of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Interstitial cells of the white matter in the inferior parietal cortex in schizophrenia: An unbiased cell-counting study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Combined electroconvulsive-clozapine therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Is risperidone a substitute for clozapine for patients who do not respond to neuroleptics?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: a preliminary case series report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

A dose-outcome analysis of risperidone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Aggressive behaviors among the institutionalized elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Antipsychotic drugs and relapse prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Risperidone in the treatment of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Risperidone augmentation of clozapine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

A selective review of recent North American long-term followup studies of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Defining treatment refractoriness in schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

The evolution of treatment resistance: biologic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drug.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Adjunctive loxapine in a clozapine-resistant cohort of schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Treatment resistant chronic psychopathology and CT scans in schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Addition of reserpine to ongoing neuroleptic exposure in chronic schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Plasma homovanillic acid as an index of central dopaminergic activity: studies in schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Olanzapine and sulpiride: a preliminary study of combination/augmentation in patients with treatment-resistant schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Clozapine: current status and role in the pharmacotherapy of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Clinical and psychopharmacologic factors influencing family burden in refractory schizophrenia. The Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

How long to wait for a response to clozapine: a comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Update on the clinical efficacy and side effects of clozapine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

An open trial of olanzapine in patients with treatment-refractory psychoses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Poor neuroleptic response in acutely exacerbated schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Clinical implications of clozapine discontinuation: report of an NIMH workshop.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

A placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Standards of care and clinical algorithms for treating schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Risperidone-reserpine combination in refractory psychosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Predictors of response to neuroleptic treatment in schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Augmentation with sulpiride for a schizophrenic patient partially responsive to clozapine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Quetiapine for refractory schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

An open trial of risperidone augmentation of partial response to clozapine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Refractory schizophrenia and atypical antipsychotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

A controlled dose comparison of haloperidol in newly admitted schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Efficacy of beta-blocker supplementation for schizophrenia: a systematic review of randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Optimal dosing with risperidone: updated recommendations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Pharmacoepidemiology of clozapine in 202 inpatients with schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

Pharmacological treatment strategies in the non-responsive schizophrenic patient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

inferred from DOI database lookup

7 January 2021

based on heuristic

A haloperidol-carbamazepine interaction in a patient with rapid-cycling bipolar disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901271-9

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0006-3223(01)01271-9

1 reference

2 August 2017

1 reference

PubMed ID

11743944